Literature DB >> 19351903

Motility induction in breast carcinoma by mammary epithelial laminin 332 (laminin 5).

Philip M Carpenter1, Anh V Dao, Zahida S Arain, Michelle K Chang, Hoa P Nguyen, Shehla Arain, Jessica Wang-Rodriguez, Soon-Young Kwon, Sharon P Wilczynski.   

Abstract

Host interactions with tumor cells contribute to tumor progression by several means. This study was done to determine whether mammary epithelium could interact with breast carcinoma by producing substances capable of inducing motility in the cancer cells. Conditioned medium of immortalized 184A1 mammary epithelium collected in serum-free conditions induced dose-dependent motility in the MCF-7 breast carcinoma cell line by both a semiquantitative scattering assay and a Boyden chamber assay. Purification of the motility factor revealed that it was laminin 332 (formerly laminin 5) by mass spectroscopy. A Western blot of the 184A1 conditioned medium using a polyclonal antibody confirmed the presence of laminin 332 in the conditioned medium. Blockage of the motility with antibodies to the laminin 332 and its receptor components, alpha(3) and beta(1) integrins, provided further evidence that tumor cell motility was caused by the laminin 332 in the conditioned medium. Invasion of MCF-7, BT-20, and MDA-MB-435 S was induced by purified laminin 332 and 184A1 conditioned medium and blocked by an anti-alpha(3) integrin antibody. Staining of carcinoma in situ from breast cancer specimens revealed that laminin 332 in the myoepithelium adjacent to the preinvasive cells provided a source of laminin 332 that could potentially encourage the earliest steps of stromal invasion. In metaplastic breast carcinomas, the presence of laminin 332-producing cells coexpressing alpha(3) integrin and the greater metastatic potential of tumors with higher laminin 332 levels suggest that laminin 332 expression is associated with aggressive features in these human breast cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351903     DOI: 10.1158/1541-7786.MCR-08-0148

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  26 in total

Review 1.  Integrin α3β1 as a breast cancer target.

Authors:  Sita Subbaram; C Michael Dipersio
Journal:  Expert Opin Ther Targets       Date:  2011-08-13       Impact factor: 6.902

Review 2.  Integrated extracellular matrix signaling in mammary gland development and breast cancer progression.

Authors:  Jieqing Zhu; Gaofeng Xiong; Christine Trinkle; Ren Xu
Journal:  Histol Histopathol       Date:  2014-03-28       Impact factor: 2.303

3.  Laminin 332 expression in breast carcinoma.

Authors:  Soon-Young Kwon; Seoung W Chae; Sharon P Wilczynski; Ahmad Arain
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-03

4.  Mismatch in mechanical and adhesive properties induces pulsating cancer cell migration in epithelial monolayer.

Authors:  Meng-Horng Lee; Pei-Hsun Wu; Jack Rory Staunton; Robert Ros; Gregory D Longmore; Denis Wirtz
Journal:  Biophys J       Date:  2012-06-19       Impact factor: 4.033

5.  Determination of alternate splicing events using the Affymetrix Exon 1.0 ST arrays.

Authors:  Sita Subbaram; Marcy Kuentzel; David Frank; C Michael Dipersio; Sridar V Chittur
Journal:  Methods Mol Biol       Date:  2010

6.  Integrin α3β1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma.

Authors:  Katherine N Gibson-Corley; Mary E Herndon; Bo Zhou; Yihan Sun; Elisabeth Gustafson-Wagner; Melissa Teoh-Fitzgerald; Frederick E Domann; Michael D Henry; Christopher S Stipp
Journal:  Mol Cancer Res       Date:  2013-09-03       Impact factor: 5.852

7.  Laminin-332-rich tumor microenvironment for tumor invasion in the interface zone of breast cancer.

Authors:  Baek Gil Kim; Hee Jung An; Suki Kang; Yoon Pyo Choi; Ming-Qing Gao; Haengran Park; Nam Hoon Cho
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

8.  Laminin 332 expression and prognosis in breast cancer.

Authors:  Philip M Carpenter; Argyrios Ziogas; Emma M Markham; Alegria S Cantillep; Rui Yan; Hoda Anton-Culver
Journal:  Hum Pathol       Date:  2018-08-17       Impact factor: 3.466

9.  Integrin α3β1 controls mRNA splicing that determines Cox-2 mRNA stability in breast cancer cells.

Authors:  Sita Subbaram; Scott P Lyons; Kimberly B Svenson; Sean L Hammond; Lorena G McCabe; Sridar V Chittur; C Michael DiPersio
Journal:  J Cell Sci       Date:  2014-01-16       Impact factor: 5.285

10.  Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion.

Authors:  Nuno Bernardes; Sofia Abreu; Filomena A Carvalho; Fábio Fernandes; Nuno C Santos; Arsénio M Fialho
Journal:  Cell Cycle       Date:  2016-04-20       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.